<?xml version="1.0" encoding="UTF-8" standalone="no"?><rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" version="2.0">

<channel>
	<title>Inside Precision Medicine</title>
	<atom:link href="https://www.insideprecisionmedicine.com/feed/" rel="self" type="application/rss+xml"/>
	<link>https://www.insideprecisionmedicine.com/</link>
	<description></description>
	<lastBuildDate>Wed, 18 Nov 2026 00:07:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.insideprecisionmedicine.com/wp-content/uploads/2022/01/IPM-FAV-ICON-hi-res-150x150.png</url>
	<title>Inside Precision Medicine</title>
	<link>https://www.insideprecisionmedicine.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<xhtml:meta content="noindex" name="robots" xmlns:xhtml="http://www.w3.org/1999/xhtml"/><item>
		<title>AMP 2026: Proof-of-Concept Data for Speedy Respiratory Illness Testing</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-proof-of-concept-data-for-speedy-respiratory-illness-testing/</link>
		
		<dc:creator><![CDATA[Corinna Singleman, PhD]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 00:07:09 +0000</pubDate>
				<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Patient Care]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=215081</guid>

					<description><![CDATA[<p>Imagine feeling sick with an unknown respiratory illness, going to urgent care, and leaving soon after with both a diagnosis and a treatment plan. This is the exact scenario that VedaBio is working toward, as opposed to the current standard, which includes hours-to-days-long waits for test results to confirm diagnosis. “It’s a story that started [&#8230;]</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-proof-of-concept-data-for-speedy-respiratory-illness-testing/">AMP 2026: Proof-of-Concept Data for Speedy Respiratory Illness Testing</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Imagine feeling sick with an unknown respiratory illness, going to urgent care, and leaving soon after with both a diagnosis and a treatment plan. This is the exact scenario that VedaBio is working toward, as opposed to the current standard, which includes hours-to-days-long waits for test results to confirm diagnosis.</p>
<p>“It’s a story that started with the problem first,” Frederic D. Sweeney, PhD, president and CEO of VedaBio, began telling <em>IPM</em> just days after presenting some of their recent data at AMP26 in Seattle, WA. He described the data from proof-of-concept studies using target amplification-free CRISPR-based molecular diagnostics technology. The assay aims to provide results within 10 minutes. Their ultimate goal, as Sweeney described, is to develop a simple-to-use diagnostic tool that can be available and used in urgent care facilities across the country.</p>
<figure id="attachment_215083" aria-describedby="caption-attachment-215083" style="width: 300px" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-215083" src="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-300x300.jpeg" alt="" width="300" height="300" srcset="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-300x300.jpeg 300w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-150x150.jpeg 150w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-768x768.jpeg 768w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-420x420.jpeg 420w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-696x696.jpeg 696w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-600x600.jpeg 600w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney-100x100.jpeg 100w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Sweeney.jpeg 800w" sizes="(max-width: 300px) 100vw, 300px" /><figcaption id="caption-attachment-215083" class="wp-caption-text">Frederic D. Sweeney, PhD, president and CEO of VedaBio</figcaption></figure>
<p>“The challenge really happens, and a lot of people say, ‘Well, point-of-care molecular is crowded.’ But my answer to that is always, ‘Well, how come, of the 65 million people that walk into an urgent care every year with a sniffle and a cough, four times out of five, you&#8217;ll walk out of there without a result’,” he said. His goal is to address this need by returning a result while the patient is still in the office with the doctor, allowing the doctor to provide specific care instructions to the patient.</p>
<p>“In order to be able to return a result in urgent care, we always talk about these five pillars of the uncompromising test,” Sweeney pointed out. These five pillars include speed, simplicity, breadth, accuracy, and economics. Their current proof of concept functions within these pillars, with Sweeney, and his colleagues working to develop a diagnostic tool that can be used to improve provider and patient experience in urgent care settings.</p>
<p>“Molecular diagnostics should not have to come with trade-offs between speed, complexity, and performance,” said Brett Robb, PhD, CSO of VedaBio. “Our goal is to challenge those limitations and bring the benefits of molecular testing closer to patients. These findings demonstrate exciting progress toward that vision and underscore the potential of our CRISPR-based approach to help redefine what is possible at the point of care.”</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_3' data-render-ad='3'></span></aside>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_4' data-render-ad='4'></span></aside>
<p>The following interview has been edited for length and clarity.</p>
<p><span style="color: #003d58;"><strong><em>IPM</em></strong>:</span> There are many at-home antigen test kits for RSV, COVID-19, and influenza A and B. Your test includes rhinovirus, which is novel. What is the benefit for a patient of going to urgent care to get the test, over taking a 15-minute nasal swab test at home?</p>
<p><strong>Sweeney</strong>: It&#8217;s a great question. I&#8217;m going to give you three different angles. True, at-home tests are ubiquitous now, and they&#8217;re all antigen tests. If you think about accuracy, which is a mix of sensitivity and specificity, antigen tests are 50% as sensitive as molecular tests. If you test yourself at home, what do you do with a positive test? I think, especially with things like flu and RSV, you still need a physician interaction to have the right treatment of care. The reason we put rhinovirus on there is that, depending on the studies, I&#8217;ve seen some studies showing that up to 75% of kids walking into urgent care have rhinovirus.</p>
<p>&nbsp;</p>
<p><span style="color: #003d58;"><strong><em>IPM</em></strong>:</span> On the other side, is the development of these tests, in some ways, perhaps a proof of concept to continue development of tests for other diseases that don&#8217;t have at-home tests?</p>
<p><strong>Sweeney: </strong>This is how we&#8217;re building toward something that&#8217;s going to be extremely comprehensive, right? But the way we think about it, always being a startup company, is like, what is the biggest bang for the buck, like beyond flu A, flu B, COVID-19? With RSV, rhinovirus, especially in urgent care, it is not a virus that is very bad; this virus does not kill you, right? But if you are a parent walking in urgent care for testing, adding this to our panel basically doubles the time where the physician can tell you, you have rhinovirus, and I will not give you an antibiotic.</p>
<p>What we can do is we can pool different results together. Basically, the way our CRISPR technology works is that we can have many, many different CRISPR enzymes and guide RNAs. We call them RNPs targeting different viruses in one result. So, you can imagine that now you can expand that panel of testing, while staying in a reimbursement environment that&#8217;s still amenable to being paid for the test. So, as you&#8217;ll see in the future, we have a respiratory virus plus, which is basically going to cover most of the other pathogens. So that prevalence that we&#8217;re looking for, maybe right at 60% now or so, we&#8217;re going to grow that to 90 to 95% plus.</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_5' data-render-ad='5'></span></aside>
<p>To come back to maybe to close the loop on the at-home testing, I think at-home testing is fine. But again, the diagnostic is only as valuable as the action that you take on it. And I think in urgent care specifically, we built our pathogen panel to focus on urgent care. We live in the world of urgent care, which we&#8217;re really driven by patient satisfaction and provider satisfaction. So that&#8217;s why we&#8217;re so excited about having rhinovirus as the first one. And then an additional nine different pathogens that you&#8217;ll see in the next test that will cover up to 90% plus of prevalence.</p>
<p>&nbsp;</p>
<p><span style="color: #003d58;"><strong><em>IPM</em></strong>:</span> Once you have the assay established and you start going to other infectious diseases, let&#8217;s say we have another COVID-19 situation, how quickly could it be for you to do some analysis and develop another diagnostic test because that was a huge detriment to the world at the beginning of the pandemic before we had effective and quick testing. <strong> </strong></p>
<p><strong>Sweeney:</strong> I love this question. The traditional techniques are PCR-based. And often what happens is that there are a couple of PCR steps. The first one is what we call a nested PCR when you have a lot of different primers and problems, and it’s very complicated to devolve that assay. And then what happens is you amplify your sample, and then you split your result. And then there&#8217;s a second amplification that provides your specificity. If you want to add a new test, then what you have to go is you have to go back to the original amplification and then revalidate your entire panel. The beauty of what we do is that the sample is split, and every single reaction is independent from one another. So what that means is that we can add another one, or we can replace one without having to revalidate. In terms of saving time, absolutely, because we don&#8217;t have to re-run the cost, right? We don&#8217;t have to revalidate the whole panel.</p>
<p>In PCR, if you amplify things for long enough, no matter where you amplify, you&#8217;ll see something, and it&#8217;s basically the delta between your signal and the background. Our assays have no background, so what we&#8217;re looking at is the separation between a signal and a flat background. And we can do that by playing around with the guide RNAs, which gives us the specificity. And we use multiple RNPs, which are the Cas enzyme and the guide complex for a single pathogen.</p>
<p>But we have a program now, and that&#8217;s one of the big parts of intellectual property: the sophistication we have around building these guides. And we have ways now to do this very efficiently; if you tell me a sequence, I can build you a guide pool, as we call it, that gives you the maximum efficiency, the maximum sensitivity.</p>
<p>And then the last thing I&#8217;ll say is that a huge advantage is that we&#8217;re using multiple RNPs. If there&#8217;s a mutation that comes in, as we experienced during Omicron, and then the mutation was in the primer, then about 50% of the assays were not good anymore. Well, because we have so many RNPs in our assays, if one basically goes away because there&#8217;s a mutation, we have a bunch of them that still work, so the decrease in sensitivity is not impacted as much. Our assays are extremely robust to genetic variation of the viruses.</p>
<p>&nbsp;</p>
<p><span style="color: #003d58;"><strong><em>IPM</em></strong>:</span> Where are you in the regulatory process to establish this as a platform that can be used in the clinic?</p>
<p><strong>Sweeney:</strong> I think we&#8217;re pretty well advanced. The cartridge is a simple piece of plastic with a few lyophilized beads in here. And I think that&#8217;s one of the most impressive things about this kit—two tubes and a cartridge. And it&#8217;s as easy to use as a SOFIA antigen test. Literally, this is what we built the system to do because the users in the field are medical technologists; they&#8217;re not lab technicians that you would see in a hospital. We had a requirement that the system has to be as easy to use as a SOFIA. So right now, where we are in development, making it more robust, building our prototype that can go into clinical trials. We have a lot of data internally on clinical samples that we showed at AMP. We have actually much more now. And then in terms of the regulatory path, there&#8217;s the path, but there&#8217;s also the experience of getting it done, right? And we&#8217;re trying to build both together.</p>
<p>&nbsp;</p>
<p><span style="color: #003d58;"><strong><em>IPM</em></strong>:</span> The size of that equipment looks really compact, like it can definitely fit in the workflow that an urgent care already has. What does that cost look like for the clinicians to have the equipment to maintain it? And then, what would that cost to patients be like? Are you already exploring how to get it approved for being covered by insurance?</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_6' data-render-ad='6'></span></aside>
<p><strong>Sweeney:</strong> So again, there&#8217;s no amplification or system, and that makes a very simple cartridge. But people tend to forget that it also makes a very simple instrument because there are, again, the requirements to run the assay. It&#8217;s quite simple to run. My engineers would hate for me to say that because they work really hard. But the premise of the assay is that we can build an instrument that we can literally give away to the provider. And that&#8217;s actually very important from a competitive standpoint. That&#8217;s our plan now. The cost of goods is low enough that the payback on our instruments is so low that we should say, ‘Hey, look, and by the way, if you&#8217;re in urgent care, I&#8217;ll give you two, in case you need more.” Each urgent care is run differently. Some have one instrument per room; some don&#8217;t.</p>
<p>My point is we have almost infinite flexibility on how to make sure that the instrument is not a pushback or it&#8217;s not a challenge for the providers to adopt, because these providers in urgent care, they work on very, very thin margins. We want to make sure that we maximize their margin.</p>
<p>That&#8217;s also now how the test comes. We&#8217;re really trying to make the test fit with the current kind of molecular reimbursement codes, which we have all the reasons to believe it will. And then it&#8217;s the old pricing strategy—we can provide, we can sell to the healthcare provider at a cost that, when they turn around and ask for a reimbursement, even after the insurers negotiate down that rate. They make a decent profit, we make a decent profit, and everybody wins along the value chain without overcharging the patient. Which is, again, at the end of the day, the patient has to come out on top. It should be a seamless experience for the patient. Whether you get another test or get our test, the patient shouldn&#8217;t see a financial difference. They should come out of there faster and with a result in their hands, and with great patient satisfaction.</p>
<p>We&#8217;ve announced recently a partnership with a group called UCP Merchant Medicine that was announced in early September. UCP Merchant Medicine is one of the largest consulting firms for urgent care—they are very focused on urgent care workflows and economics. We&#8217;re working together to show real-world evidence in terms of using their clinics and how our test would fit into their workflows and the economics. And then going forward, we&#8217;ll work with them to make sure that their operating clients have preferred allocation to our test. We provide a test that not only drives patient satisfaction, but from the urgent care provider to test for one of the very first time they say, “Oh, that&#8217;s not going to be a cost center for us. It&#8217;s going to be a profit center.” And all of this is doable.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-proof-of-concept-data-for-speedy-respiratory-illness-testing/">AMP 2026: Proof-of-Concept Data for Speedy Respiratory Illness Testing</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Lexeo Reports Good Early Results for Cardiomyopathy Gene Therapy</title>
		<link>https://www.insideprecisionmedicine.com/topics/precision-medicine/lexeo-reports-good-early-results-for-cardiomyopathy-gene-therapy/</link>
		
		<dc:creator><![CDATA[Helen Albert]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 19:09:12 +0000</pubDate>
				<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Patient Care]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Research]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=215061</guid>

					<description><![CDATA[<p>Lexeo Therapeutics reports good efficacy and safety results for its arrhythmogenic cardiomyopathy gene therapy for patients with <i>PKP2</i> gene mutations in a Phase I/II trial.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/precision-medicine/lexeo-reports-good-early-results-for-cardiomyopathy-gene-therapy/">Lexeo Reports Good Early Results for Cardiomyopathy Gene Therapy</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>New York biotech Lexeo Therapeutics reports good Phase I/II data for its adeno-associated virus (AAV) vector gene therapy for treatment of PKP2 arrhythmogenic cardiomyopathy, an inherited heart disorder that leads to abnormal heart rhythms.</p>
<p>The<a href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-positive-interim-phase-iii-data-and" target="_blank" rel="noopener"> study</a> was only small and early stage, but five of seven patients in the high-dose group reported improvements in symptoms and the therapy, currently known as LX2020, was well tolerated across the participants.</p>
<p>PKP2-associated arrhythmogenic cardiomyopathy is an inherited disease in which defective connections between heart muscle cells lead to scarring, abnormal rhythms and potentially sudden death. Around 75% of all cases of arrhythmogenic cardiomyopathy are thought to be caused by mutations in the <em>PKP2</em> gene, totaling around 60,000 people in the U.S. who are affected by this disorder.</p>
<p>There are existing treatments for this condition including rhythm-control drugs, catheter ablation, and implanted defibrillators to manage complications, but these do not correct the underlying genetic defect, and no disease-modifying treatment is currently approved.</p>
<p>Lexeo’s LX2020 gene therapy uses an AAVrh10 vector to supply a functional <em>PKP2 </em>gene to patients with this type of cardiomyopathy, which if successful could become the first disease modifying therapy for this condition.</p>
<p>This week Lexeo reported interim results from its Phase I/II study of 10 patients with PKP2-associated arrhythmogenic cardiomyopathy who received LX2020. Three patients received a low dose (2×10<sup>13</sup> vg/kg) and seven a high dose (6×10<sup>13</sup> vg/kg) of the gene therapy.</p>
<p>The study is fully enrolled, but follow-up is due to continue for four years. By October 15 of this year, nine patients had at least 12 months follow up, and one had nine months follow up.</p>
<p>The results showed that in the high-dose patients short bursts of rapid ventricular rhythm fell by an average of 80% and six patients improved during the follow up period. Premature ventricular beats fell by 44% and five patients improved during the follow up period.</p>
<p>There were signs of improvement in cardiac function, as assessed by magnetic resonance imaging, in most of the high dose group. Cardiac biopsies also showed dose-dependent uptake of LX2020 and good expression of the PKP2 protein.</p>
<p>There were some elevations in liver function tests in the high dose group, but no significant complement activation and no patient discontinued the study. One patient did have a grade 3 ventricular tachycardia event three months after dosing, but this was probably due to their condition rather than the therapy.</p>
<p>These early results are promising but require confirmation and validation in larger trials. In the same statement, Lexeo announced that the FDA is open to using non-sustained ventricular tachycardia “as a primary surrogate endpoint in an accelerated approval pivotal study.” The company hopes to begin this pivotal study next year.</p>
<p>Lexeo is not the only company using a gene therapy approach to treat PKP2-associated arrhythmogenic cardiomyopathy. Tenaya Therapeutics is testing a competing <em>PKP2</em> gene therapy, also currently at Phase Ib/II and also reported <a href="https://investors.tenayatherapeutics.com/news-releases/news-release-details/positive-interim-data-cohorts-1-and-2-tenayas-ridgetm-1-phase" target="_blank" rel="noopener">early positive results</a> from a small group of patients this year.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/precision-medicine/lexeo-reports-good-early-results-for-cardiomyopathy-gene-therapy/">Lexeo Reports Good Early Results for Cardiomyopathy Gene Therapy</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Could Genome Testing at Birth Identify Diseases Years Before Symptoms Appear?</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/could-genome-testing-at-birth-identify-diseases-years-before-symptoms-appear/</link>
		
		<dc:creator><![CDATA[Alice McCarthy]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 17:27:32 +0000</pubDate>
				<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=214996</guid>

					<description><![CDATA[<p>Researchers at Rady Children’s Institute for Genomic Medicine found that rapid and ultra-rapid whole-genome sequencing yielded positive findings in 36.2% of adolescents tested. Eight of those findings could have been identified through a newborn genomic screening program, raising questions about opportunities for earlier diagnosis.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/could-genome-testing-at-birth-identify-diseases-years-before-symptoms-appear/">Could Genome Testing at Birth Identify Diseases Years Before Symptoms Appear?</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p data-pm-slice="1 1 []">Whole-genome sequencing has become an important tool for diagnosing genetic diseases in critically ill newborns and young children. But what about adolescents who receive a genetic diagnosis years later? Could some of those conditions have been identified at birth?</p>
<p>New research from Rady Children’s Institute for Genomic Medicine suggests that rapid and ultra-rapid whole-genome sequencing can provide diagnostic answers during adolescence. The findings also raise questions about whether broader newborn screening could shorten the time to diagnosis for some patients.</p>
<p>The study, presented by Jennifer Schleit, PhD, at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, examined 177 adolescents aged 13 to 19 who underwent clinical genomic testing between 2021 and 2025. Researchers retrospectively reviewed results from 117 patients (66.1%) who received rapid whole-genome sequencing and 60 (33.9%) who underwent ultra-rapid sequencing. Positive findings were reported in 64 patients (36.2%), while 39 (22%) received uncertain results and 74 (41.8%) had negative findings. Cardiac and neurological conditions were the most common reasons for testing, with positive findings reported in 37.7% and 35.4% of these patients, respectively.</p>
<h4><strong>An understudied age group</strong></h4>
<p>Most research on rapid whole-genome sequencing has focused on newborns and critically ill young children, where identifying an underlying genetic disorder quickly can guide urgent treatment decisions. Although genomic sequencing is also used in older children, relatively few studies have examined adolescents as a distinct population.</p>
<p>One previous study, <a href="https://www.gimjournal.org/article/S1098-3600(23)00893-6/fulltext" target="_blank" rel="noopener">NYCKidSeq</a>, evaluated genomic sequencing in children and young adults with suspected genetic disorders. Among 238 adolescents and young adults older than 12, researchers reported a molecular diagnostic yield of 14.7%.</p>
<p>The Rady study&#8217;s 36.2% positive finding rate was considerably higher, although differences in patient selection, testing approaches, and definitions of positive findings make direct comparisons difficult.</p>
<h4><strong>Implications for newborn screening</strong></h4>
<p>Beyond evaluating diagnostic findings in adolescents, Schleit and colleagues investigated whether some of those conditions could have been identified through BeginNGS, a whole-genome sequencing-based newborn screening program developed at Rady. BeginNGS evaluates 507 early-onset genetic disorders and reports variants classified as pathogenic or likely pathogenic, meaning they are known or strongly suspected to cause disease.</p>
<p>When researchers compared the adolescents&#8217; results with the program&#8217;s current reporting criteria, they found that eight of the 64 positive findings (13%) would have qualified for reporting through BeginNGS.</p>
<p>The findings are relevant to ongoing efforts to expand newborn screening beyond the conditions included in conventional screening panels. Unlike diagnostic genomic testing, which is generally performed when a genetic disorder is suspected, newborn genomic screening aims to identify certain conditions before symptoms emerge. However, detecting a genetic condition earlier does not necessarily mean that treatment or outcomes would improve. That depends on the disorder, the availability of effective interventions, and whether action before symptoms develop would offer a clinical benefit. The study also involved adolescents already selected for clinical testing, meaning its diagnostic yield cannot be generalized to the broader newborn population.</p>
<p>The findings underscore the value of genomic testing beyond infancy while providing evidence that a subset of genetic diagnoses made during adolescence could have been established years earlier.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/could-genome-testing-at-birth-identify-diseases-years-before-symptoms-appear/">Could Genome Testing at Birth Identify Diseases Years Before Symptoms Appear?</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>AMP 2026: Has the $100 Liquid Biopsy Arrived?</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-has-the-100-liquid-biopsy-arrived/</link>
		
		<dc:creator><![CDATA[Jonathan D. Grinstein, PhD]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 17:17:18 +0000</pubDate>
				<category><![CDATA[Informatics]]></category>
		<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=215006</guid>

					<description><![CDATA[<p>Technology advancements in low-cost sequencing, multimodal analysis, and fragmentomics are reducing the price of liquid biopsies.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-has-the-100-liquid-biopsy-arrived/">AMP 2026: Has the $100 Liquid Biopsy Arrived?</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span data-contrast="auto"><strong>SEATTLE</strong>—</span><span class="TextRun SCXW145690802 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SpellingErrorV2Themed SCXW145690802 BCX0">Fragmentomics</span><span class="NormalTextRun SCXW145690802 BCX0">. That one word was one of the buzzier terms at the <span style="font-weight: 400;">Association for Molecular Pathology (AMP) 2026 Annual Meeting, representing</span></span></span><span class="TextRun SCXW145690802 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW145690802 BCX0"> a broader</span><span class="NormalTextRun SCXW145690802 BCX0"> theme of extracting more biological information from increasingly inexpensive sequencing technologies.</span></span><span class="EOP Selected SCXW145690802 BCX0" data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">Traditional liquid biopsies largely focus on detecting mutations or alterations in DNA methylation patterns in cell-free DNA (cfDNA). Fragmentomics takes a different approach, examining how cfDNA breaks apart. Research dating back to 2015 demonstrated that DNA fragmentation is not random but reflects chromatin organization and epigenetic regulation. These patterns can reveal information about tissue of origin, cellular activity, and disease that mutations alone might miss.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">The implications for oncology are considerable. Tumor-derived DNA often exhibits different fragmentation patterns than DNA released by healthy cells. By examining these patterns across the genome, researchers may be able to detect cancer without identifying specific mutations, determine a tumor&#8217;s tissue of origin, and monitor treatment response or molecular residual disease.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">An increasingly promising strategy is multimodal liquid biopsy, which combines fragmentomics with mutations, copy-number alterations, methylation patterns, and other molecular features. Rather than relying on a single biomarker, these approaches extract complementary information from the same sample, potentially improving diagnostic sensitivity without necessarily requiring more sequencing.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<figure id="attachment_215014" aria-describedby="caption-attachment-215014" style="width: 300px" class="wp-caption alignright"><img decoding="async" class="wp-image-215014 size-medium" src="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/julia-1-copy-e1794935584581-300x274.jpg" alt="Julia Burnier - McGill" width="300" height="274" srcset="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/julia-1-copy-e1794935584581-300x274.jpg 300w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/julia-1-copy-e1794935584581-461x420.jpg 461w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/julia-1-copy-e1794935584581.jpg 600w" sizes="(max-width: 300px) 100vw, 300px" /><figcaption id="caption-attachment-215014" class="wp-caption-text">Julia Burnier, PhD, Associate Professor of Pathology and Oncology at McGill University [McGill University]</figcaption></figure>
<h4 aria-level="4"><strong>More information from less sequencing </strong></h4>
<p><span data-contrast="auto">At AMP, Julia Burnier, PhD, of McGill University, presented research involving esophageal adenocarcinoma, an aggressive cancer that has historically been difficult to monitor through liquid biopsy. These tumors can shed relatively little circulating tumor DNA (ctDNA), particularly in localized disease, making mutation-based detection challenging.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">Burnier&#8217;s team studied approximately 50 patients, combining mutation detection, copy-number alterations, and fragmentomic features into a machine-learning classifier. Together, these signals achieved approximately 85% ctDNA detection, outperforming individual approaches. But the more intriguing finding came when the researchers asked whether all that information was necessary. By identifying the most informative features, they found that copy-number and fragmentomic signals derived solely from shallow whole-genome sequencing (WGS) could retain useful discriminatory power, potentially eliminating the need for more expensive targeted sequencing. </span>The estimated sequencing cost was approximately $100.</p>
<p><span data-contrast="auto">Stanford University&#8217;s Hanlee P. Ji, MD, offered a complementary perspective, focusing on maximizing the information extracted from individual DNA molecules. </span><span data-contrast="auto">Using long-read nanopore sequencing, his team simultaneously analyzed DNA fragmentation, methylation, and hydroxymethylation in cerebrospinal fluid (CSF) from patients with lung cancer brain metastases. The researchers identified fragmentation patterns that distinguished cancer patients from healthy controls, including nucleosome-associated signatures that behaved differently in blood and CSF.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">Although preliminary, the findings illustrate how a single sequencing approach can capture multiple layers of molecular information without requiring separate assays for each biomarker. </span><span data-contrast="auto">Where Burnier demonstrated the potential of inexpensive sequencing to capture diagnostically useful signals, Ji highlighted how richer molecular measurements could reveal additional disease biology. Together, their presentations illustrated two complementary strategies: reducing the cost of obtaining clinically useful information and increasing the amount of information extracted from each assay.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<h4 aria-level="4"><strong>Can sequencing deliver a $100 liquid biopsy? </strong></h4>
<p><span data-contrast="auto">Today&#8217;s commercial liquid biopsies can cost thousands of dollars. Guardant Health, for example, lists a cash-pay price of $8,455 for its Guardant360 Liquid CDx comprehensive genomic profiling test, while Medicare&#8217;s initial payment for the Shield colorectal cancer screening assay was $1,495. These are different pricing measures, rather than laboratory production costs, but they illustrate the gap between commercial testing and Burnier&#8217;s approximately $100 sequencing estimate.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">Ultima Genomics recently announced that its UG200 platform can sequence a human genome at approximately 30-fold coverage for $60 in sequencing consumables. But the company isn&#8217;t alone in approaching the economics needed for inexpensive liquid biopsy. A 2026 modeling study comparing sequencing technologies for cfDNA-based cancer detection estimated consumables costs of approximately $4 per genome-equivalent coverage on Ultima&#8217;s UG100, compared with $15 on Illumina&#8217;s NovaSeq X and $73 on Oxford Nanopore&#8217;s PromethION. PacBio&#8217;s short-read Onso platform was estimated at approximately $29.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">These figures, converted to U.S. dollars from prices collected in November 2025, reflect theoretical sequencing capacity and consumables costs rather than experimentally validated liquid biopsy workflows. They nevertheless suggest that shallow whole-genome sequencing could be performed for substantially less than $100 on multiple platforms, particularly at high sample volumes. Whether those savings translate into an equally inexpensive clinical assay depends on sequencing depth, library preparation, sample throughput, and the molecular information required for diagnosis.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">There are technical differences beyond cost. Illumina&#8217;s established paired-end sequencing workflows are well suited to measuring cfDNA fragment lengths and genomic coverage patterns. Ultima&#8217;s UG200 now also supports paired-end sequencing, potentially expanding its compatibility with fragmentomic analyses. Whether either platform can preserve the particular molecular features required by Burnier&#8217;s classifier at a given sequencing depth would need to be established experimentally.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<figure id="attachment_215016" aria-describedby="caption-attachment-215016" style="width: 300px" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-215016" src="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/photocache.5887-300x300.jpg" alt="hanlee ji" width="300" height="300" srcset="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/photocache.5887-300x300.jpg 300w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/photocache.5887-150x150.jpg 150w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/photocache.5887-100x100.jpg 100w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/photocache.5887.jpg 350w" sizes="(max-width: 300px) 100vw, 300px" /><figcaption id="caption-attachment-215016" class="wp-caption-text">Hanlee P. Ji, MD, Professor of Medicine (Oncology) at Stanford University School of Medicine [Stanford University]</figcaption></figure>
<p><span data-contrast="auto">Long-read sequencing presents a different proposition. Oxford Nanopore, the technology used in Ji&#8217;s research, can analyze DNA sequence and certain epigenetic modifications directly, potentially eliminating separate chemical conversion or enrichment steps. PacBio&#8217;s HiFi technology also enables highly accurate sequencing and the detection of DNA modifications. However, their economics are less straightforward. The same modeling study estimated approximately $72.69 per genome-equivalent coverage for Oxford Nanopore&#8217;s PromethION, substantially higher than the short-read alternatives. PacBio&#8217;s Onso was estimated at $28.64, but Onso is a short-read system, not one of the company&#8217;s long-read HiFi platforms.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">These differences matter because cfDNA is naturally fragmented, with many molecules measuring roughly 150–200 base pairs. For liquid biopsy, the potential advantage of long-read platforms may therefore lie less in sequencing exceptionally long molecules than in extracting additional information from each fragment. Could those additional measurements compensate for higher sequencing costs? Potentially, if they improve diagnostic performance or replace other laboratory assays. But neither Oxford Nanopore nor PacBio has established that its long-read technology can deliver a complete, clinically validated $100 cancer liquid biopsy.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">For short-read platforms, meanwhile, low sequencing costs don&#8217;t automatically translate into equally inexpensive tests. Sample collection, cfDNA extraction, library preparation, quality control, computational analysis, clinical interpretation, personnel, and laboratory overhead all contribute to the final price. A study evaluating Ultima&#8217;s UG100 for metagenomic pathogen detection in CSF provides an instructive example. Researchers estimated approximately $60 in sequencing costs and $40 in additional reagent expenses per sample. Although unrelated to cancer detection, the work illustrates how inexpensive sequencing can bring laboratory reagent costs toward $100 without necessarily covering the full expense of a clinical test.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">For Burnier&#8217;s assay, several questions remain unresolved. She did not specify which sequencing platform her team used, the precise sequencing depth, or whether the approximately $100 estimate included library preparation. Nor would a low-cost shallow-WGS approach necessarily work for every liquid biopsy application. Broad copy-number alterations and fragmentomic signatures may be detectable at relatively low coverage, whereas identifying extremely rare tumor-specific mutations, particularly in molecular residual disease, generally demands much greater analytical sensitivity.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">The emerging picture is therefore more nuanced than any manufacturer&#8217;s headline sequencing price suggests. Several platforms may be approaching the economics necessary for inexpensive liquid biopsy, but their suitability depends on the molecular signals being measured and the clinical questions being asked.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<h4 aria-level="4"><strong>Right information, right price </strong></h4>
<p><span data-contrast="auto">The larger question is whether a $100 liquid biopsy needs to do everything today&#8217;s more expensive tests can do. </span><span data-contrast="auto">An inexpensive assay designed to detect broad cancer-associated signals might be useful for certain applications, while highly sensitive mutation-specific testing remains necessary for others. And sometimes, sequencing isn&#8217;t necessary at all. Burnier illustrated that point with research involving HPV-associated cancers. In oropharyngeal cancer, her team developed an inexpensive digital PCR assay to detect HPV DNA in blood and saliva, enabling treatment-response monitoring and showing promise for identifying patients at increased risk of recurrence.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">The researchers subsequently expanded their work to cervical cancer, where access to screening remains a significant challenge in remote and underserved communities. In unpublished findings presented at AMP, Burnier described how plasma samples distinguished patients with cancer from those without, while urine and self-collected vaginal swabs helped differentiate high-grade from low-grade precancerous lesions. Unlike the esophageal cancer study, these assays relied on targeted HPV DNA detection rather than multimodal fragmentomics. For patients facing geographic, financial, or other barriers to conventional screening, inexpensive tests using self-collected samples could expand access to molecular diagnostics, provided their clinical performance is validated.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">These findings underscore that liquid biopsies don&#8217;t necessarily require blood, deep sequencing, or sophisticated computational pipelines to provide clinically relevant information. Likewise, greater analytical sophistication doesn&#8217;t automatically translate into greater clinical utility. Detecting additional molecular signals offers little advantage if those measurements don&#8217;t  improve treatment decisions and, ultimately, patient outcomes. And affordability matters only if the test performs reliably in its intended clinical setting. </span><span data-contrast="auto">The challenge is finding the right balance between analytical sensitivity, biological information, clinical utility, and cost.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-contrast="auto">Perhaps the future of liquid biopsy isn&#8217;t about extracting every possible piece of information from a sample but determining how much information we actually need and how cheaply we can obtain it. A $100 liquid biopsy may be technically within reach for certain applications. But the more consequential question is what $100 can reliably tell us about a patient&#8217;s disease and whether that&#8217;s enough to improve their care.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-has-the-100-liquid-biopsy-arrived/">AMP 2026: Has the $100 Liquid Biopsy Arrived?</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>AMP 2026: 700,000 Whole Tumor Transcriptomes Reveal Gene Fusion Targets</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-700000-whole-tumor-transcriptomes-reveal-gene-fusion-targets/</link>
		
		<dc:creator><![CDATA[Jonathan D. Grinstein, PhD]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 16:51:53 +0000</pubDate>
				<category><![CDATA[Informatics]]></category>
		<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=214997</guid>

					<description><![CDATA[<p>Two Caris studies demonstrate how comprehensive RNA-seq can identify drug development targets and patients who may benefit from existing therapies.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-700000-whole-tumor-transcriptomes-reveal-gene-fusion-targets/">AMP 2026: 700,000 Whole Tumor Transcriptomes Reveal Gene Fusion Targets</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;"><strong>SEATTLE</strong>—In April,</span><a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/hussam-al-kateb-inside-mayo-clinics-molecular-diagnostic-revolution/?utm_source=chatgpt.com" target="_blank" rel="noopener"> <span style="font-weight: 400;">Mayo Clinic Laboratories introduced a whole-transcriptome sequencing (WTS) assay</span></a><span style="font-weight: 400;"> that interrogates approximately 20,000 genes, with clinical reporting focused on 1,445—a substantial expansion from its previous 138-gene sarcoma panel. The motivation was straightforward: cancer genomics was advancing faster than targeted diagnostic panels could keep up. As new fusions emerged, existing assays risked missing clinically relevant alterations, particularly in sarcomas and central nervous system tumors.</span></p>
<p><span style="font-weight: 400;">Seven months later, two studies presented by Caris Life Sciences at the Association for Molecular Pathology (AMP) 2026 Annual Meeting in Seattle, Washington, demonstrated the potential of broader sequencing. One analyzed 698,406 solid tumors, identifying novel </span><i><span style="font-weight: 400;">ALK</span></i><span style="font-weight: 400;"> and </span><i><span style="font-weight: 400;">FGFR2</span></i><span style="font-weight: 400;"> fusion partners associated with outcomes comparable to established partners following matched therapy. &#8220;We&#8217;re determining whether or not these fusions are pathogenic or likely pathogenic or of uncertain significance,&#8221; Jaclyn Hechtman, MD, medical director at Caris and co-author of both studies, said. &#8220;We have an evidence team that matches all of these fusions up with how relevant these are in treatment.&#8221;</span></p>
<p><span style="font-weight: 400;">The other characterized rare </span><i><span style="font-weight: 400;">PAK</span></i><span style="font-weight: 400;">-family fusions in ovarian, fallopian tube, and primary peritoneal serous carcinomas, identifying potential cancer drivers. </span><span style="font-weight: 400;">&#8220;[Dr. Hechtman’s] poster really captures the widespread utility and power of WTS,&#8221; Mark G. Evans, MD, director of molecular pathology at Caris and an author of the second study, told <em>Inside Precision Medicine</em>. &#8220;My study looks at the application for a rare finding and how that might have therapeutic implications down the line.&#8221;</span></p>
<p><span style="font-weight: 400;">Together, the developments reflect a shift from searching for predefined alterations toward comprehensively identifying fusions and determining their clinical significance.</span></p>
<figure id="attachment_215018" aria-describedby="caption-attachment-215018" style="width: 284px" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-215018 size-medium" src="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Hechtman_Jaclyn-Frances_180604_024-e1794900599800-284x300.jpg" alt="Jaclyn Hechtman" width="284" height="300" srcset="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Hechtman_Jaclyn-Frances_180604_024-e1794900599800-284x300.jpg 284w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Hechtman_Jaclyn-Frances_180604_024-e1794900599800-398x420.jpg 398w, https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Hechtman_Jaclyn-Frances_180604_024-e1794900599800.jpg 403w" sizes="auto, (max-width: 284px) 100vw, 284px" /><figcaption id="caption-attachment-215018" class="wp-caption-text">Jaclyn Hechtman, MD, Medical Director at Caris Life Sciences [Caris Life Sciences]</figcaption></figure>
<h4><b>Beyond targeted fusion panels</b></h4>
<p><span style="font-weight: 400;">Gene fusions can serve as diagnostic markers and therapeutic targets, but conventional testing may miss them. DNA-based assays can struggle with rearrangements in long or repetitive intronic regions, while targeted RNA panels may overlook unexpected fusion partners. “With DNA-based testing, it can be very hard to capture all relevant introns, and breakpoints and fusions usually occur at the introns,&#8221; explained Hechtman in an interview with </span><i><span style="font-weight: 400;">Inside Precision Medicine</span></i><span style="font-weight: 400;">. &#8220;Sometimes introns are long, repetitive.&#8221;</span></p>
<p><span style="font-weight: 400;">WTS broadens detection by examining RNA across the transcriptome rather than predefined targets. &#8220;When you&#8217;re using RNA, you don&#8217;t have to worry about the introns,&#8221; Hechtman said. &#8220;And then when you are using whole transcriptome, you get to see everything, and so you get to see the rare fusions.&#8221;</span></p>
<p><span style="font-weight: 400;">Some fusions have diagnostic value, particularly in sarcomas, while others, including kinase fusions, can inform targeted treatment. But detecting a fusion is only the first step. At Caris, molecular geneticists and pathologists assess its technical validity, biological plausibility, and pathogenicity before an evidence team evaluates potential therapies and clinical trials. </span></p>
<h4><b>An extensive landscape of rare fusions</b></h4>
<p><span style="font-weight: 400;">In &#8220;</span><span style="font-weight: 400;">Whole Transcriptome Sequencing Identifies Novel Clinically Actionable Gene Fusions Across 698,406 Solid Tumors with Comparable Outcomes to Canonical Fusion Partners</span><span style="font-weight: 400;">,&#8221; Caris researchers analyzed tumors profiled between 2019 and 2026.</span></p>
<p><span style="font-weight: 400;">Fusion transcripts appeared in 503,460 tumors (72.1%). Among fusion-positive tumors, 37,325 harbored pathogenic or likely pathogenic fusions, while 34,671 contained fusions with therapeutic or diagnostic significance. More than 91% of actionable fusion pairs were absent from the ClinVar and CIViC reference datasets used. </span><i><span style="font-weight: 400;">ALK</span></i><span style="font-weight: 400;">, </span><i><span style="font-weight: 400;">FGFR2</span></i><span style="font-weight: 400;">, and </span><i><span style="font-weight: 400;">FGFR3</span></i><span style="font-weight: 400;"> were among the most frequently identified actionable fusion genes.</span></p>
<p><span style="font-weight: 400;">These previously unlisted combinations illustrate the diversity of fusion partners rather than necessarily representing entirely new therapeutic targets. &#8220;We&#8217;re finding novel partners or fusions that are actionable,&#8221; Hechtman said, citing &#8220;<em>ALK</em> fusions in non-small cell lung cancer that may have been missed because the fusion partner is novel&#8221; and </span><i><span style="font-weight: 400;">FGFR2</span></i><span style="font-weight: 400;"> fusions in cholangiocarcinoma.</span></p>
<p><span style="font-weight: 400;">The researchers also examined whether patients with novel fusion partners benefited from existing therapies. Using linked clinical and claims data, they found that patients with novel or canonical </span><i><span style="font-weight: 400;">ALK</span></i><span style="font-weight: 400;"> or </span><i><span style="font-weight: 400;">FGFR2</span></i><span style="font-weight: 400;"> partners receiving matched tyrosine kinase inhibitors (TKIs) had comparable survival. Both groups experienced longer survival than patients receiving non-TKI treatments. &#8220;These patients have comparable survival to known canonical fusion partners,&#8221; Hechtman said. &#8220;So detecting these novel fusion partners is important for select patients.&#8221;</span></p>
<p><span style="font-weight: 400;">Although observational data cannot establish causation, the findings suggest that some uncommon fusion partners retain therapeutic relevance. Whereas Mayo&#8217;s assay development emphasized broader detection and diagnostic utility, Caris&#8217;s analysis connects certain novel fusions with treatment outcomes.</span></p>
<h4><b><em>PAK</em> fusions reveal potential ovarian cancer drivers</b></h4>
<p><span style="font-weight: 400;">The second study, &#8220;</span><span style="font-weight: 400;">Detection of <em>PAK</em> Family Gene Fusions in Serous Carcinoma of Ovary, Fallopian Tube, and Peritoneum</span><span style="font-weight: 400;">,&#8221; identified 237 tumors with </span><i><span style="font-weight: 400;">PAK1</span></i><span style="font-weight: 400;">, </span><i><span style="font-weight: 400;">PAK2</span></i><span style="font-weight: 400;">, or </span><i><span style="font-weight: 400;">PAK3</span></i><span style="font-weight: 400;"> fusions, representing just 0.17% of the ovarian, fallopian tube, and primary peritoneal serous carcinomas studied. </span><span style="font-weight: 400;">These fusions occurred in high-grade and borderline or low-grade tumors, most commonly involving </span><i><span style="font-weight: 400;">DLG1</span></i><span style="font-weight: 400;"> and </span><i><span style="font-weight: 400;">GAB2</span></i><span style="font-weight: 400;"> partners.</span></p>
<p><span style="font-weight: 400;">The </span><i><span style="font-weight: 400;">PAK</span></i><span style="font-weight: 400;"> genes encode p21-activated kinases, which regulate cytoskeletal organization, proliferation, and cell motility. The fusions retained kinase-encoding regions, suggesting potential functional significance.</span></p>
<figure id="attachment_215019" aria-describedby="caption-attachment-215019" style="width: 240px" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-full wp-image-215019" src="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/11/Evans-M.jpg" alt="mark evans - caris" width="240" height="300" /><figcaption id="caption-attachment-215019" class="wp-caption-text">Mark G. Evans, MD, Director of Molecular Pathology at Caris Life Sciences [Caris Life Sciences]</figcaption></figure>
<p><span style="font-weight: 400;">Caris&#8217;s database of more than a million sequenced tumors enabled researchers to assemble an unusually large cohort of these rare alterations. &#8220;Thanks to the over a million tumors that we&#8217;ve sequenced at Caris, we have a pretty large cohort of this very rare fusion in ovarian, fallopian tube, and primary peritoneal serous carcinomas,&#8221; Evans told <em>Inside Precision Medicine</em>.</span></p>
<p><span style="font-weight: 400;">The researchers also identified distinct genomic patterns. High-grade tumors frequently harbored </span><i><span style="font-weight: 400;">TP53</span></i><span style="font-weight: 400;"> alterations, while <em>PAK-</em>fusion-positive low-grade tumors often lacked the MAP kinase pathway mutations typically associated with low-grade serous carcinoma. &#8220;There is mutual exclusivity in terms of the genetic alterations that you typically see in low-grade serous carcinomas and these tumors that have the <em>PAK</em> fusions,&#8221; Evans said. &#8220;That might suggest that this is the driver or the molecular alteration targeted by a potential therapy.&#8221;</span></p>
<p><span style="font-weight: 400;">Hechtman suggested that tumors without established MAP kinase pathway alterations might be particularly relevant for further investigation. &#8220;In the cases that are MAPK pathway negative or wild-type, low-grade ovarian serous carcinomas are probably candidates for these PAK-family fusions,&#8221; she said.</span></p>
<p><span style="font-weight: 400;">Potential connections between PAK signaling, MAP kinase activation, and YAP1, an effector of Hippo signaling, provide additional biological rationale. &#8220;There&#8217;s a mechanistic reason for why something as rare as something found in less than 1% of ovarian, fallopian tube, and primary peritoneal serous carcinomas might actually be important,&#8221; Evans said.</span></p>
<h4><b>Target identification is just the start</b></h4>
<p><span style="font-weight: 400;">Unlike </span><i><span style="font-weight: 400;">ALK</span></i><span style="font-weight: 400;"> and </span><i><span style="font-weight: 400;">FGFR2</span></i><span style="font-weight: 400;"> fusions, PAK-family fusions are not validated therapeutic biomarkers in ovarian cancer. Although PAK inhibitors are under investigation, their development faces challenges. &#8220;These PAK proteins have widespread expression in many cells within the body and high homology between the proteins,&#8221; Evans explained. &#8220;So targeting them is complicated.&#8221;</span></p>
<p><span style="font-weight: 400;">Their similarity and widespread expression can contribute to off-target toxicity, complicating selective drug development. &#8220;This is how discoveries are made,&#8221; Evans said. &#8220;You find a new or rare target for a potential therapy, refine it </span><i><span style="font-weight: 400;">in vitro</span></i><span style="font-weight: 400;">, </span><i><span style="font-weight: 400;">in vivo</span></i><span style="font-weight: 400;">, and then eventually put it to market for approval.&#8221;</span></p>
<p><span style="font-weight: 400;">The distinction between identifying a molecular target and developing an effective treatment highlights both the promise and limitations of comprehensive sequencing.</span></p>
<p><span style="font-weight: 400;">Mayo&#8217;s assay, with 1,445 reportable genes and reported sensitivity, specificity, and accuracy of 99%, 96%, and 98%, respectively, emphasizes diagnostic applications. Caris&#8217;s studies demonstrate how large-scale profiling can also reveal uncommon therapeutic opportunities and potential new cancer drivers.</span></p>
<p><span style="font-weight: 400;">Neither approach establishes that WTS should replace targeted testing. Cost, analytical complexity, sample quality, and clinical relevance remain important considerations. &#8220;There are very rare alterations, but there is an increasing number of very rare yet targetable alterations over time,&#8221; Hechtman said.</span></p>
<p><span style="font-weight: 400;">The two Caris studies illustrate different stages of clinical translation: novel </span><i><span style="font-weight: 400;">ALK</span></i><span style="font-weight: 400;"> and </span><i><span style="font-weight: 400;">FGFR2</span></i><span style="font-weight: 400;"> partners may identify additional patients eligible for existing treatments, while <em>PAK</em> fusions could inform future drug discovery. </span><span style="font-weight: 400;">As WTS becomes more accessible, the central question is shifting from how many additional fusions can be detected to how many ultimately change treatment decisions and improve patient outcomes.</span></p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-700000-whole-tumor-transcriptomes-reveal-gene-fusion-targets/">AMP 2026: 700,000 Whole Tumor Transcriptomes Reveal Gene Fusion Targets</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>DNA Methylation Profiling May Predict Recurrence Risk in Uterine Cancer</title>
		<link>https://www.insideprecisionmedicine.com/topics/oncology/dna-methylation-profiling-may-predict-recurrence-risk-in-uterine-cancer/</link>
		
		<dc:creator><![CDATA[Laura Cowen]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 16:45:40 +0000</pubDate>
				<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=215024</guid>

					<description><![CDATA[<p>Researchers identified an epigenetic signature that accurately divided low-grade CNL/NSMP endometrial tumors into three recurrence-risk groups, potentially helping identify patients who need closer surveillance after surgery.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/oncology/dna-methylation-profiling-may-predict-recurrence-risk-in-uterine-cancer/">DNA Methylation Profiling May Predict Recurrence Risk in Uterine Cancer</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Researchers at the University of California, San Francisco (UCSF) have identified an epigenetic signature that could help predict recurrence risk in patients with low-grade endometrioid adenocarcinoma whose tumors fall into the copy number low/non-specific molecular profile (CNL/NSMP) molecular subgroup.</p>
<p>The findings, which were presented at the <a href="https://amp26.amp.org/" target="_blank" rel="noopener">Association for Molecular Pathology’s 2026 annual meeting</a>, reveal previously unrecognized molecular heterogeneity within this common tumor subtype and suggest that DNA methylation profiling could help identify patients at increased risk of recurrence who may benefit from closer surveillance following surgery.</p>
<p>Endometrial cancer is the most common gynecologic cancer in the U.S. and the 4<sup class="wp-sup-text">th</sup> most common cancer overall in women. The American Cancer Society estimates 68,270 new cases of endometrial cancer will be diagnosed in 2026 with 14,450 women expected to die from the disease.</p>
<p>In 2013, a landmark study within The Cancer Genome Atlas classified endometrioid adenocarcinomas into four molecular subgroups based on the presence of specific mutations or copy number alteration profiles: Ultramutated, hypermutated, copy number-high, and CNL/NSMP.</p>
<p>The most common subgroup is the CNL/NSMP group, which comprises around 40–50% of endometrial cancers. Presenting author Matthew Zunitch, MD, PhD, resident physician in Anatomic and Clinical Pathology at UCSF described this subtype as a “leftover” group, where tumors are placed if they lack the defining alterations of the other three groups.</p>
<p>Although tumors in this molecular category generally follow a favorable clinical course, a subset do recur and gene expression data and tumor mutational profiling has not identified reliable biomarkers to predict this recurrence.</p>
<p>“Methylation profiling has already been used to explore or reinforce differences between the four molecular classifications; therefore, we knew it played a role, but experiments designed for this purpose are less likely to reveal subtleties or subclassifications within each group,” Zunitch told <em>Inside Precision Medicine</em>. “We suspected there may be underappreciated heterogeneity within this ‘leftover’ group and designed our study to look for it.”</p>
<p>Zunitch and team carried out CpG methylation profiling on 219 untreated, uterine primary, CNL/NSMP, FIGO grade 1 to 2 endometrioid adenocarcinomas. They identified around 1500 differentially methylated regions (DMRs) between tumors that ultimately recurred and non-recurrent tumors.</p>
<p>Using the top 700 DMRs, the researchers defined a recurrence-associated methylation signature and built a regression model to score tumors according to this signature. The scoring system splits tumors into those at low-, intermediate-, or high-risk for recurrence.</p>
<p>“In a general sense, the three groups differ in the types of genomic regions that are methylated, and in the direction of those methylation changes,” said Zunitch. “Additionally, we found differences in the rates of a small handful of recurrent mutations and recurrent copy number alterations between the groups.”</p>
<p>He reported that the new three-group system achieved an accuracy of approximately 90% for predicting recurrence, with an area under the receiver operating characteristic curve of approximately 0.99.</p>
<p>“If you look at the rare instances where the model misassigned a tumor, this occurred at the boundaries between intermediate-risk and one of the other groups,” Zunitch remarked. “The model never mistook a low-risk tumor for a high-risk tumor or vice versa, which would be an important feature in the clinical setting.”</p>
<p>The team also found that tumors within the high-risk methylation group were more likely to have <em>CTNNB1</em> mutations than tumors in the other groups, which Zunitch said is in line with previous work from other researchers who reported <em>CTNNB1</em> mutations as a risk factor for endometrial cancer recurrence.</p>
<p>The scoring system will now be validated in an external cohort. If the accuracy of risk prediction is proven, DNA methylation testing could easily be added to pathologic and molecular testing workflows for patients with endometrial cancer, as it is a technique that most molecular diagnostics laboratories are familiar with, noted Zunitch.</p>
<p>“Our findings could enable clinicians to identify a subset of patients with elevated risk of recurrence, which in turn could enable personalized surveillance plans after hysterectomy,” he concluded. “Perhaps the simplest example is offering high-risk patients follow-up visits at shorter intervals.”</p>
<p>However, he cautioned that any potential benefit of increased surveillance would need to be weighed against the risks of additional exposures such as additional biopsies or imaging studies.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/oncology/dna-methylation-profiling-may-predict-recurrence-risk-in-uterine-cancer/">DNA Methylation Profiling May Predict Recurrence Risk in Uterine Cancer</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>New Blood Test Could Make Measuring Advanced Alzheimer’s Disease More Accessible</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/new-blood-test-could-make-measuring-advanced-alzheimers-disease-more-accessible/</link>
		
		<dc:creator><![CDATA[Alice McCarthy]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 03:59:06 +0000</pubDate>
				<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=214994</guid>

					<description><![CDATA[<p>Researchers have developed a new blood test that could make it easier to assess advanced Alzheimer's disease. The immunoassay accurately identified advanced tau pathology, offering a more practical way to measure a biomarker previously requiring specialized mass spectrometry.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/new-blood-test-could-make-measuring-advanced-alzheimers-disease-more-accessible/">New Blood Test Could Make Measuring Advanced Alzheimer’s Disease More Accessible</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Researchers have developed a new blood test that could make it easier to assess advanced Alzheimer’s disease, using a simpler laboratory method to measure a biomarker previously detectable only with specialized mass spectrometry.</p>
<p>The test measures eMTBR-tau, a fragment of tau protein that earlier studies linked to the accumulation of neurofibrillary tangles in the brain. Unlike existing blood tests that primarily identify earlier Alzheimer’s-related changes, eMTBR-tau may provide information about more advanced pathology associated with cognitive decline.</p>
<p>In a study of 728 participants published in <a href="https://jamanetwork.com/journals/jama/fullarticle/2856953?guestAccessKey=48f19c82-9b8c-4a6f-b498-ee47ca459109" target="_blank" rel="noopener"><em>JAMA</em></a>, researchers at Banner Sun Health Research Institute in Arizona, Lund University in Sweden, and collaborating institutions found that the new immunoassay accurately identified advanced tau pathology, with performance comparable to mass spectrometry. The assay was developed in collaboration with Alamar Biosciences.</p>
<p>Alzheimer’s disease is characterized by two pathological hallmarks: amyloid-beta plaques and neurofibrillary tangles composed of aggregated tau protein. Although blood tests measuring phosphorylated tau 217 (p-tau217) can identify Alzheimer’s-related amyloid pathology, they provide less information about the extent of tau tangle accumulation, which is more closely associated with cognitive impairment and disease severity.</p>
<p>Earlier research established eMTBR-tau243 as a promising blood biomarker of tau pathology. Studies published in 2025 and 2026 linked higher concentrations to tau accumulation and faster cognitive decline, but measuring the biomarker required specialized mass spectrometry available in relatively few laboratories.</p>
<p>“One of the most challenging tasks in Alzheimer’s disease diagnosis is to establish in a patient with cognitive impairment that Alzheimer’s pathology is not just present, but that is present in a sufficiently advanced biological stage to be a likely explanation for symptoms,” said co-senior author Niklas Mattsson-Carlgren, MD, PhD, a neurologist at Skåne University Hospital and researcher at Lund University.</p>
<p>To evaluate the immunoassay, investigators analyzed blood samples from 521 brain donors in two U.S. autopsy cohorts and 207 participants in imaging studies conducted in Canada and Sweden.</p>
<p>In the autopsy cohorts, eMTBR-tau concentrations were 25.2 to 50.5 times higher among individuals with the most advanced tau pathology, classified as Braak stage VI, compared with those at stages I–II. These stages describe how far tau tangles have spread through the brain, with the most advanced stages involving widespread accumulation in the cerebral cortex.</p>
<p>In one imaging cohort, concentrations were nearly 60 times higher in participants with advanced tau pathology than in those without detectable tau abnormalities on PET imaging. The researchers noted that many measurements in the comparison groups were below the assay’s quantification limit, although the differences remained substantial in more conservative analyses.</p>
<p>The assay also accurately distinguished participants with tau pathology detected by PET, achieving areas under the curve of 0.96 to 0.99, comparable to mass spectrometry. In an additional autopsy analysis, eMTBR-tau was more closely associated with overall tau tangle burden than either conventional p-tau217 or brain-derived p-tau217.</p>
<p>The new immunoassay requires just 35 µL of plasma, compared with 1.5 mL for mass spectrometry, and avoids its complex sample preparation requirements.</p>
<p>“While p-tau217 detects early signs of Alzheimer&#8217;s disease, eMTBR-tau measures how far tau tangles have spread,” said senior author Nicholas Ashton, PhD, senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute. “Together, they could help doctors make better treatment decisions and identify the right patients for clinical trials.”</p>
<p>The findings suggest that the two markers could complement one another, with p-tau217 identifying earlier Alzheimer’s-related changes and eMTBR-tau providing information about more advanced tau pathology.</p>
<p>A scalable test could eventually help researchers stage Alzheimer’s disease and select patients for clinical trials, particularly where tau-PET imaging is unavailable.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/new-blood-test-could-make-measuring-advanced-alzheimers-disease-more-accessible/">New Blood Test Could Make Measuring Advanced Alzheimer’s Disease More Accessible</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Blood Protein Signature Could Improve Diabetes and Cardiometabolic Risk Prediction</title>
		<link>https://www.insideprecisionmedicine.com/topics/precision-medicine/blood-protein-signature-could-improve-diabetes-and-cardiometabolic-risk-prediction/</link>
		
		<dc:creator><![CDATA[Alisa Kirkin]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 20:13:31 +0000</pubDate>
				<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Research]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=214983</guid>

					<description><![CDATA[<p>A new study suggests that combining blood protein profiling with routine clinical measurements could improve the identification of people at risk of diabetes and other chronic diseases.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/precision-medicine/blood-protein-signature-could-improve-diabetes-and-cardiometabolic-risk-prediction/">Blood Protein Signature Could Improve Diabetes and Cardiometabolic Risk Prediction</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p style="font-weight: 400;">A new blood-based approach to measuring insulin resistance could help identify individuals at risk of developing type 2 diabetes and other chronic diseases before symptoms emerge. Researchers have developed a protein-based prediction model that captures metabolic dysfunction across multiple organs, potentially offering a more comprehensive assessment of cardiometabolic health than conventional clinical markers.</p>
<p style="font-weight: 400;">The findings, published in <em><a href="https://www.nature.com/articles/s42255-026-01662-1" target="_blank" rel="noopener">Nature Metabolism</a></em>, suggest that circulating proteins could provide a scalable approach to personalized disease risk assessment.</p>
<h4 style="font-weight: 400;"><strong>Capturing insulin resistance through blood proteins</strong></h4>
<p style="font-weight: 400;">Insulin resistance occurs when tissues become less responsive to <a href="https://www.insideprecisionmedicine.com/?s=insulin&amp;filter=&amp;page=null" target="_blank" rel="noopener">insulin</a>, impairing the body&#8217;s ability to regulate blood glucose. Although it is a major contributor to type 2 diabetes, it also plays a role in cardiovascular, kidney, and liver diseases.</p>
<p style="font-weight: 400;">Accurately measuring insulin sensitivity remains challenging. The gold-standard hyperinsulinemic-euglycemic clamp requires controlled insulin and glucose infusions, making it impractical for routine clinical use. Simpler measurements are available but provide only indirect estimates of insulin resistance.</p>
<p style="font-weight: 400;">To address this limitation, researchers led by scientists at the University of Copenhagen analyzed blood samples from 161 individuals with varying degrees of insulin sensitivity using several complementary proteomics technologies.</p>
<p style="font-weight: 400;">The analysis identified hundreds of circulating proteins associated with insulin sensitivity, reflecting biological processes in the liver, adipose tissue, skeletal muscle, and immune system.</p>
<p style="font-weight: 400;">Using these findings, the team developed a machine-learning model combining 13 proteins with three routinely available clinical measurements, including HbA1c and blood lipid levels.</p>
<h4 style="font-weight: 400;"><strong>Predicting more than diabetes</strong></h4>
<p style="font-weight: 400;">The researchers subsequently applied their model to approximately 20,000 participants in the UK Biobank to investigate whether the protein signature could predict future disease.</p>
<p style="font-weight: 400;">The model predicted type 2 diabetes more accurately than the triglyceride-to-HDL cholesterol ratio, a commonly used surrogate marker of insulin resistance. Its performance was comparable to HbA1c, which remains an established indicator of diabetes risk.</p>
<p style="font-weight: 400;">However, the model&#8217;s broader predictive capabilities may be its most important contribution.</p>
<p style="font-weight: 400;">Unlike HbA1c, which primarily reflects blood glucose regulation, the protein-based score also predicted conditions including fatty liver disease, cardiovascular disease, and chronic kidney disease.</p>
<p style="font-weight: 400;">These findings were further supported by an independent cohort of approximately 1,700 individuals followed for nearly two decades. Although an established glucose tolerance-based measure remained a stronger predictor of diabetes, the proteomic model demonstrated broader associations with several chronic disease outcomes.</p>
<p style="font-weight: 400;">The researchers suggest that the findings reflect how &#8220;systemic insulin resistance extends beyond glycemic dysregulation and classical cardiometabolic disease alone.&#8221;</p>
<h4 style="font-weight: 400;"><strong>Toward personalized metabolic risk assessment</strong></h4>
<p style="font-weight: 400;">An additional finding was that exercise appeared to shift circulating protein patterns toward a more insulin-sensitive profile, suggesting that proteomic signatures might eventually help monitor responses to preventive interventions.</p>
<p style="font-weight: 400;">Nevertheless, the approach is not yet ready for clinical implementation. The initial cohorts were relatively small and predominantly of European ancestry, while the influence of medications on protein profiles was not systematically assessed. Larger, more diverse studies and prospective clinical validation will be needed to establish whether the model improves patient outcomes beyond existing risk assessment tools.</p>
<p style="font-weight: 400;">In summary, the findings point toward a broader role for plasma proteomics in precision medicine. Rather than relying exclusively on glucose measurements, clinicians could eventually use molecular signatures to identify underlying metabolic dysfunction and better tailor preventive strategies to individual patients.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/precision-medicine/blood-protein-signature-could-improve-diabetes-and-cardiometabolic-risk-prediction/">Blood Protein Signature Could Improve Diabetes and Cardiometabolic Risk Prediction</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Exposure to Agent Orange Increased Risk for Parkinson’s Disease</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/exposure-to-agent-orange-increased-risk-for-parkinsons-disease/</link>
		
		<dc:creator><![CDATA[Helen Albert]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 20:03:30 +0000</pubDate>
				<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Patient Care]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Research]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=214987</guid>

					<description><![CDATA[<p>Exposure to the wartime chemical herbicide Agent Orange significantly increased risk for developing Parkinson's disease and other synucleinopathies in later life. </p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/exposure-to-agent-orange-increased-risk-for-parkinsons-disease/">Exposure to Agent Orange Increased Risk for Parkinson&#8217;s Disease</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A large study of veterans exposed to Agent Orange during the Vietnam War era confirms such exposure significantly increased the risk of developing Parkinson’s disease and related conditions.</p>
<p>The study, published in <em><a href="https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamaneurol.2026.4219?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamaneurol.2026.4219" target="_blank" rel="noopener">JAMA Neurology</a></em>, showed self-reported exposure to Agent Orange increased risk of Parkinson’s disease, rapid eye movement (REM) sleep behavior disorder, and dementia with Lewy bodies by 44%, 78%, and 66%, respectively, compared with no exposure.</p>
<p>Individuals with a greater degree of exposure, for example, those working with the chemical, had an even greater increase in risk for developing these conditions.</p>
<p>Agent Orange was a mixture of two weedkillers, 2,4-D and 2,4,5-T, in roughly equal proportions. It was formulated for military use to strip leaves from trees and destroy vegetation during the Vietnam War between 1950 and 1975. The manufacture of its 2,4,5-T ingredient produced contamination with TCDD, a highly toxic dioxin.</p>
<p>“Parkinson disease is the fastest growing neurological disorder worldwide and outpacing the increases expected due to aging and improved diagnosis,” write the study authors.</p>
<p>“Increasing attention is being paid to environmental and military specific factors. Spraying of the dioxin-contaminated herbicide Agent Orange during the Vietnam War was one of the largest toxic exposure events of the 20<sup class="wp-sup-text">th</sup> century.”</p>
<p>While some case control studies and others linked to its components have been carried out that suggest a link between exposure and Parkinson’s disease, large scale research linking Agent Orange exposure with this and related conditions is limited.</p>
<p>In this study, the researchers analyzed U.S. Veterans Affairs medical records for 4.47 million Vietnam-era veterans, who were followed up for an average of 12.5 years between 1999 and 2022 looking for signs of Parkinson’s or the related disorders REM sleep behavior disorder, and dementia with Lewy bodies.</p>
<p>They compared veterans with documented Agent Orange exposure, who had largely self-reported through a registry, with those without documented exposure. The team also looked separately at a group of 7,600 veterans whose records indicated direct handling or spraying of Agent Orange or service in units responsible for spraying.</p>
<p>After 15 years of follow-up, veterans with registry-reported Agent Orange exposure had an estimated 4.6 additional Parkinson’s cases per 1,000 people compared with those without documented exposure. For veterans with direct or occupational exposure, the difference was 15.4 cases per 1,000, more than double the rate seen in individuals with registry reported exposure to the chemical.</p>
<p>This is the first large-scale study of the association between exposure to Agent Orange and Parkinson’s in Vietnam-era veterans, strengthening previously limited direct evidence. The U.S. already recognizes Parkinson’s as presumptively service-connected for qualifying exposed veterans, but these findings provide firmer epidemiological support.</p>
<p>“Although 2,4,5-T usage was phased out during the 1970s and banned in most countries by 1985, 2,4-D continues to be one of the most-used herbicides globally and is registered in over 90 countries,” write Samuel Goldman, MD, University of California, and co-authors of an accompanying editorial in the same journal, drawing attention to potential continuing risks linked to the components of Agent Orange.</p>
<p>“Use of 2,4-D is widespread and extends far beyond farms to turf grass, highways, golf courses, gardens, and yards. Although not all studies report an association, <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/797977?utm_campaign=articlePDF&amp;utm_medium=articlePDFlink&amp;utm_source=articlePDF&amp;utm_content=jamaneurol.2026.4218" target="_blank" rel="noopener">Tanner and colleagues</a> found that North American individuals who worked with the weed killer had a 160% increased risk of Parkinson disease.”</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/exposure-to-agent-orange-increased-risk-for-parkinsons-disease/">Exposure to Agent Orange Increased Risk for Parkinson&#8217;s Disease</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Blood Biomarker Shows Promise for Detecting Advanced Chronic Traumatic Encephalopathy</title>
		<link>https://www.insideprecisionmedicine.com/topics/molecular-dx/blood-biomarker-shows-promise-for-detecting-advanced-chronic-traumatic-encephalopathy/</link>
		
		<dc:creator><![CDATA[Alice McCarthy]]></dc:creator>
		<pubDate>Sat, 14 Nov 2026 04:00:47 +0000</pubDate>
				<category><![CDATA[Molecular Dx]]></category>
		<category><![CDATA[News & Features]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.insideprecisionmedicine.com/?p=214941</guid>

					<description><![CDATA[<p>A blood biomarker originally developed for Alzheimer’s disease shows promise for detecting advanced chronic traumatic encephalopathy (CTE), potentially paving the way for diagnosis in living patients.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/blood-biomarker-shows-promise-for-detecting-advanced-chronic-traumatic-encephalopathy/">Blood Biomarker Shows Promise for Detecting Advanced Chronic Traumatic Encephalopathy</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A new test for chronic traumatic encephalopathy (CTE) can detect advanced disease with near-perfect accuracy, a major step forward for a neurodegenerative disease currently only diagnosable after death.</p>
<p>Researchers from Washington University School of Medicine in St. Louis found that a blood biomarker for Alzheimer’s disease can also detect advanced CTE with high accuracy. The research, published in <em><a href="https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.24689" target="_blank" rel="noopener">JAMA</a></em>, could lead to a test to diagnose CTE in living patients, facilitating clinical trials for CTE treatments.</p>
<p>To date, CTE has only been diagnosed in deceased individuals. A major challenge for researchers of the disease as well as for those working on potential treatments is that there currently is no validated test to confirm whether a living patient has CTE. This has severely limited the ability to conduct clinical trials for CTE, as well as to determine whether experimental treatments are having any effect.</p>
<p>Previous research has focused on blood biomarkers such as phosphorylated tau (p-tau181 and p-tau217), neurofilament light chain (NfL), total tau, and inflammatory proteins. Some have shown associations with repetitive head impacts or neurological symptoms, but reliably distinguishing CTE from other brain disorders has remained difficult.</p>
<p>The new test is based on a protein fragment called eMTBR-tau243, which the researchers found to be a biomarker for the abnormal accumulation of tau protein in the brains of people with Alzheimer’s disease. In healthy brains, tau protein helps to stabilize the structures within neurons. But in people with CTE and other neurodegenerative diseases, tau protein can form abnormal aggregates that can cause brain degeneration.</p>
<p>Both Alzheimer’s disease and CTE are characterized by the presence of three-repeat (3R) and four-repeat (4R) tau protein. Thus, the biomarker eMTBR-tau243, which detects abnormal tau protein accumulation in Alzheimer’s disease, could also be used to detect the same pathology in CTE.</p>
<p>The study included 229 participants with cerebrospinal fluid and blood samples collected from four U.S.-based biorepositories. For many individuals, samples had been collected prior to death and post-mortem diagnosis confirmed that the individual had advanced CTE.</p>
<p>An unexpected finding connected CTE to the study, according to the researchers. During an initial analysis of the data, the researchers identified a single patient with high levels of eMTBR-tau243 but no Alzheimer’s disease-related pathology at autopsy. A subsequent review of the patient’s neuropathology records identified advanced CTE.</p>
<p>Median levels of eMTBR-tau243 in blood of 11 patients with autopsy-confirmed CTE were 1.93 fmol/L compared to 0.29 fmol/L in cognitively unimpaired controls. In CTE patients, levels of eMTBR-tau243 increased with disease severity, reaching 3.36 fmol/L in stage IV CTE.</p>
<p>The test had an AUC of 0.97 for distinguishing stage III and IV CTE from controls. The test had much lower AUC for distinguishing stage I CTE from controls (AUC 0.64).</p>
<p>Washington University researchers have also found that in some cases of frontotemporal lobar degeneration, a disease of the brain that affects behavior and language, there are elevated levels of the biomarker in cases of inherited forms of the disease that feature mixed 3R/4R tau pathology.</p>
<p>A combination of a history of repetitive head impacts, negative results for other biomarkers for Alzheimer’s disease, and elevated levels of eMTBR-tau243 would be needed to identify people with CTE. This test could also be used to monitor the disease and determine the efficacy of new treatments.</p>
<p>C2N Diagnostics, the company that Washington University licensed the technology to, has already developed a blood test for Alzheimer’s disease that was recently cleared by the FDA for use as an aid in the diagnosis of Alzheimer’s disease. However, the eMTBR-tau243 assay has not been validated for use in the diagnosis of CTE.</p>
<p>This is a preliminary study. Only six patients with advanced CTE were included in the study, and CTE cannot be distinguished from Alzheimer’s disease on the basis of elevated eMTBR-tau243 alone, since the two diseases can co-exist in the same patient.</p>
<p>While the study is preliminary, the ability to test for CTE-associated pathology in a blood sample could revolutionize how CTE is diagnosed, studied, and treated. Larger studies will be needed to confirm these findings and to determine if the biomarker can detect earlier stages of the disease.</p>
<p>The post <a href="https://www.insideprecisionmedicine.com/topics/molecular-dx/blood-biomarker-shows-promise-for-detecting-advanced-chronic-traumatic-encephalopathy/">Blood Biomarker Shows Promise for Detecting Advanced Chronic Traumatic Encephalopathy</a> appeared first on <a href="https://www.insideprecisionmedicine.com">Inside Precision Medicine</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>